Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
NCT06153368
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
Cadonilimab+mFOLFIRINOX
Sponsor
The First Affiliated Hospital with Nanjing Medical University